收藏切换
Efficacy and safety of recombinant human brain natriuretic peptide in different heart failure patients
收藏切换
Weiyan GUO, Yuanji WANG, Shiwan DUAN, Yongwei LI*, Juan LYU, Yamei LI
World Clinical Drug | 2022, 43(1) : 39 - 44
Less
收藏切换
World Clinical Drug | 2022, 43(1): 39-44
• Article •
Efficacy and safety of recombinant human brain natriuretic peptide in different heart failure patients
Full
Weiyan GUO, Yuanji WANG, Shiwan DUAN, Yongwei LI*, Juan LYU, Yamei LI
Affiliations
  • Department of Pharmacy, Xi'an NO.1 Hospital, Xi'an 710002, Shaanxi Province, China
Published: 2022-01-10 doi: 10.13683/j.wph.2022.01.008
Outline
收藏切换
Objective

To analyze the clinical efficacy of recombinant human brain Natriuretic peptide (RH-BNP) in patients with different heart failure, in order to provide more evidence for the clinical application of Rh-BNP.

Methods

Using retrospective analysis, for patients with heart failure treated in Xi'an First Hospital from January 2018 to December 2018, the New York Heart Association (NYHA) and Kay were used. Killip's cardiac function was graded, and N-terminal probrain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-cTnT) before and after the use of rh-BNP), creatine kinase isoenzyme (CK-MB), myoglobin (MYO) and other biomarkers level to analyze, record the occurrence of adverse reactions, and analyze the patient's treatment status.

Results

The levels of NT-proBNP, hs-cTnT, CK-MB, and MYO in patients with NYHA and Killip cardiac function classification heart failure using rh-BNP were significantly reduced (P<0.05). Comparing the results of treatment between the two groups, NT-proBNP was lower in patients with Killip cardiac function classification heart failure (P<0.05); the levels of hs-cTnT, CK-MB and MYO in patients with NYHA function classification heart failure were lower (P<0.05). There was no significant difference in the incidence of adverse reactions and the effectiveness of treatment between the two groups (P>0.05).

Conclusion

rh-BNP is also safe and effective for NYHA and Killip cardiac function grading patients with heart failure, and it is worthy of clinical application.

recombinant human brain natriuretic peptide  /  heart failure  /  New York Heart Association classification  /  Killip classification
郭未艳, 王园姬, 段石顽, 李勇卫, 吕娟, 李亚美. 不同心力衰竭患者使用重组人脑利钠肽的疗效及安全性分析. 世界临床药物, 2022 , 43 (1) : 39 -44 . DOI: 10.13683/j.wph.2022.01.008
Weiyan GUO, Yuanji WANG, Shiwan DUAN, Yongwei LI, Juan LYU, Yamei LI. Efficacy and safety of recombinant human brain natriuretic peptide in different heart failure patients[J]. World Clinical Drug, 2022 , 43 (1) : 39 -44 . DOI: 10.13683/j.wph.2022.01.008
Year 2022 volume 43 Issue 1
12
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.01.008
  • Receive Date:2020-10-09
  • Online Date:2026-11-19
  • Published:2022-01-10
Article Data
Affiliations
History
  • Received:2020-10-09
  • Revised:2021-12-01
Funding
Affiliations
    Department of Pharmacy, Xi'an NO.1 Hospital, Xi'an 710002, Shaanxi Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.01.008
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT